*Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated January 26, 2021 (the "**Prospectus**") issued by MicroPort CardioFlow Medtech Corporation (the "**Company**").*

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and Hong Kong Securities Clearing Company Limited ("**HKSCC**") take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares.

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in Hong Kong, the United States or elsewhere. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended, supplemented or otherwise modified from time to time (the "**U.S. Securities Act**"). The securities may not be offered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities by the Company in the United States.*

MICROPORT CARDIOFLOW MEDTECH CORPORATION

微创心通医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2160)

FULL EXERCISE OF THE OVER-ALLOTMENT OPTION

FULL EXERCISE OF THE OVER-ALLOTMENT OPTION

The Company announces that, on February 5, 2021 (after trading hours), the Over-allotment Option described in the Prospectus has been fully exercised by the Joint Global Coordinators (for themselves and on behalf of the International Underwriters) in respect of an aggregate of 30,843,000 additional Shares (the "**Over-allotment Shares**"), representing 15% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option. The Over-allotment Shares will be allotted and issued by the Company at HK$12.20 per Share (excluding brokerage of 1.0%, SFC transaction levy of 0.0027% and the Stock Exchange trading fee of 0.005%), being the Offer Price per Share under the Global Offering. The Over-allotment Shares will be used to facilitate the return of 30,843,000 Shares to Shanghai MicroPort, which were used to cover over-allocation of Shares in the International Offering.

APPROVAL OF LISTING

Approval for the listing of and permission to deal in the Over-allotment Shares has already been granted by the Listing Committee. Listing of and dealing in such Over-allotment Shares are expected to commence on the Main Board of the Stock Exchange at 9:00 a.m. on February 10, 2021 (Hong Kong time).

SHAREHOLDING STRUCTURE OF THE COMPANY UPON COMPLETION OF THE FULL EXERCISE OF THE OVER-ALLOTMENT OPTION

The shareholding structure of the Company immediately before and immediately after completion of the full exercise of the Over-allotment Option is as follows:

	Immediately before the completion of the full exercise of the Over-allotment Option		**Immediately after the completion of the full exercise of the Over-allotment Option**	
Shareholder	**Number of Shares**	**Approximate % of the Company's issued share capital**	**Number of Shares**	**Approximate % of the Company's issued share capital**
Shanghai MicroPort [(1)]	1,078,650,680	45.59%	1,078,650,680	45.00%
CF Management Global Limited	97,123,880	4.10%	97,123,880	4.05%
Stride and Strive Limited	25,795,840	1.09%	25,795,840	1.08%
Miracle Medical Limited	10,318,300	0.44%	10,318,300	0.43%
Shanghai Huahao	191,681,040	8.10%	191,681,040	8.00%
CICC Kangrui	181,592,220	7.67%	181,592,220	7.58%
Huatai Ruihe	60,530,700	2.56%	60,530,700	2.53%
Jipintang	28,727,280	1.21%	28,727,280	1.20%
SDIC Chuanghe	21,716,420	0.92%	21,716,420	0.91%
Qianyi Investment	150,000,000	6.34%	150,000,000	6.26%
Haitong Fund	75,000,000	3.17%	75,000,000	3.13%
CMP	92,081,040	3.89%	92,081,040	3.84%
AUT	46,040,520	1.95%	46,040,520	1.92%
LBC	27,624,300	1.17%	27,624,300	1.15%
CRF	26,795,560	1.13%	26,795,560	1.12%
Gamnat	18,416,200	0.78%	18,416,200	0.77%
Gortune	18,416,200	0.78%	18,416,200	0.77%
Happy Soul	9,208,100	0.39%	9,208,100	0.38%
CDG [(2)]	828,740	0.04%	828,740	0.03%
Cornerstone investors[(3)]	79,433,000	3.40%	79,433,000	3.30%
Other public shareholders	126,187,000	5.33%	157,030,000	6.55%
Total	2,366,167,020	100%	2,397,010,020	100%

Notes:

(1) Includes the 30,843,000 Shares lent to J.P. Morgan Securities plc under the Stock Borrowing Agreement.

(2) Only includes the Shares acquired by CDG before the Global Offering.

(3) These refer to all cornerstone investors as set out in the section headed "Cornerstone Investors" in the Prospectus. The shareholding of each cornerstone investor immediately before the allotment of the Over-allotment Shares is set out in the Company's allotment results announcement dated February 3, 2021. The Over-allotment Shares to be issued by the Company will not affect the number of Shares held by each cornerstone investor, and will have a dilutive effect on the shareholding of the cornerstone investors on a pro rata basis.

USE OF PROCEEDS

The additional net proceeds of approximately HK$361.2 million to be received by the Company from the allotment and issue of the Over-allotment Shares, after deduction of the underwriting commissions and other estimated expenses payable by the Company in connection with the full exercise of the Over-allotment Option, will be used by the Company for the purposes as set out in the section headed "Future Plans and Use of Proceeds" in the Prospectus.

PUBLIC FLOAT

Immediately after the completion of the Global Offering and after the full exercise of the Over-allotment Option, the Company will continue to comply with the public float requirements under Rules 8.08(1)(a) and 18A.07 of the Listing Rules.

The Company will make a further announcement after the end of the stabilization period in connection with the Global Offering pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong).

By order of the Board of Directors
MicroPort CardioFlow Medtech Corporation
Luo Qiyi
Chairman

Hong Kong, February 7, 2021

As at the date of this announcement, the executive Directors are Mr. Chen Guoming, Ms. Yan Luying and Mr. Wu Guojia, the non-executive Directors are Dr. Luo Qiyi, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Jiang Hualiang and Ms. Sun Zhixiang.